Your doctor mentioned Ozempic, your friend swears by Wegovy, and now you're staring at two names wondering if they're the same thing, or if one is secretly better. Here's the reassuring part: you're not missing some obvious distinction. These two medications are more alike than almost any other pair on the market.
In fact, Ozempic and Wegovy are the same active drug, made by the same company. The real differences come down to what each one is FDA-approved to do, the maximum dose, and how insurance treats them. Let's break it down clearly.
Are Ozempic and Wegovy the same thing?
The short answer most searchers want first: Ozempic and Wegovy contain the exact same active ingredient, semaglutide, a GLP-1 receptor agonist made by Novo Nordisk. Chemically, the molecule injected is identical. What separates them is the FDA-approved purpose and the dosing.
Semaglutide works by mimicking a gut hormone called GLP-1. It helps regulate blood sugar, slows how fast your stomach empties, and reduces appetite, which is why the same molecule is useful for both diabetes and weight management.
- Same active ingredient: semaglutide (a GLP-1 receptor agonist)
- Same manufacturer: Novo Nordisk
- Different FDA-approved indications and maximum doses
What is each one approved for?
This is the core distinction. Ozempic was FDA-approved in 2017 for type 2 diabetes. Wegovy was approved in 2021 for chronic weight management in adults with obesity or overweight.
Because they share a molecule, Ozempic is frequently prescribed off-label for weight loss. But only Wegovy is actually FDA-approved for that purpose, a distinction that matters for both safety labeling and insurance coverage.
Wegovy also carries an indication Ozempic does not have for the obesity population. In March 2024, the FDA approved Wegovy to reduce the risk of major adverse cardiovascular events in adults with known heart disease who are overweight or obese.
How do the doses differ?
Both are once-weekly injections, but they titrate to different maximum doses. Ozempic tops out at 2.0 mg per week for diabetes. Wegovy titrates up to 2.4 mg per week for weight loss. A higher-dose version, Wegovy HD (7.2 mg), was FDA-approved in March 2026.
With any semaglutide, the dose is increased gradually over several weeks. This slow ramp-up is designed to help your body adjust and reduce side effects, and the exact schedule should always come from your prescribing clinician, never from a chart online.
How well does semaglutide work for weight loss?
The weight-management evidence comes largely from the STEP trials, which studied the 2.4 mg dose used in Wegovy. In the STEP 1 trial published in the New England Journal of Medicine (1,961 adults over 68 weeks), semaglutide produced a mean body-weight reduction of 14.9% versus 2.4% for placebo, and 86% of participants lost at least 5% of their body weight.
The results held up over time. In the 2-year STEP 5 trial, mean weight loss was 15.2% with semaglutide versus 2.6% with placebo, a difference that shows the effect is durable over 104 weeks rather than a short-term drop.
Because Ozempic is the same molecule at a slightly lower maximum dose, people often see meaningful weight loss on it too, which is exactly why it gets prescribed off-label. But the formal weight-loss trial data sit with the Wegovy dose.
What are the side effects?
The side-effect profiles overlap heavily because the drug is the same. Gastrointestinal symptoms are the most common for both, and they tend to be most noticeable when you first start or step up a dose.
In the STEP 5 trial, GI adverse events occurred in 82.2% of semaglutide patients versus 53.9% on placebo, and were mostly mild-to-moderate. Most people find these symptoms ease as their body adjusts.
- Nausea
- Vomiting
- Diarrhea
- Constipation
Which one is right for you?
There's no universal winner, because the right choice depends on why you're taking it. If your primary goal is managing type 2 diabetes, Ozempic is the on-label option. If the goal is chronic weight management, Wegovy is the FDA-approved formulation, and it carries that added cardiovascular benefit for people with existing heart disease.
Insurance often follows these labels closely, sometimes covering one indication and not the other, so coverage can end up driving the practical decision as much as the medicine does.
These are prescription medications with real risks and benefits, so the decision belongs in a conversation with a licensed clinician who knows your history. If you'd like a clinician-guided starting point, Nolla can help connect you to personalized care.
Medical Disclaimer: This article is for informational purposes only and does not constitute medical advice. Always consult with a qualified healthcare provider before starting any new skincare treatment, especially if you have underlying health conditions, are pregnant, or are taking medications.
